A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone

Journal of Clinical Psychiatry

Volumn 70, Issue 4, 2009, Pages 487-499

  Newcomer, John W ^a   Ratner, Robert E ^b   Eriksson, Jan W ^c   Emsley, Robin ^d   Meulien, Didier ^e   Miller, Frank ^e   Leonova Edlund, Julia ^e   Leong, Ronald W ^f   Brecher, Martin ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

^e ASTRAZENECA R AND D   (Sweden)

^f ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSION; DIZZINESS; DRUG WITHDRAWAL; DYSPNEA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PANIC; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIBENZOTHIAZEPINES; FEMALE; GLUCOSE; HUMANS; INSULIN; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; TRIGLYCERIDES; YOUNG ADULT;

EID: 66349111159     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04132     Document Type: Article

References (30)

1. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006 Apr;3(2):A42
2. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007;298:1794-1796 (Pubitemid 47598448)
3. Cohen D, Stolk RP, Grobbee DE, et al. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006;29:786-791 (Pubitemid 44115295)
4. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-912
5. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32 (Pubitemid 41587460)
6. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(suppl 1):1-93
7. Van Gaal LF. Long-term health considerations in schizophrenia: Metabolic effects and the role of abdominal adiposity. Eur Neuropsychopharmacol 2006 Sep;16(suppl 3):S142-S148 (Pubitemid 44177766)
8. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223 (Pubitemid 41345943)
9. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004;65(suppl 18):36-46
10. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480-491 (Pubitemid 44166336)
11. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
12. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22 (Pubitemid 44234064)
13. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care 2007;30(suppl 1):S4-S41
14. Mari A, Pacini G, Murphy E, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001;24:539-548 (Pubitemid 32198427)
15. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470 (Pubitemid 29418240)
16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419 (Pubitemid 15018832)
17. Seltzer HS, Allen EW, Herron AL Jr, et al. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967;46:323-335
18. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol 1988 Jul;4(suppl A):5A-10A
19. Dobiasova M. Atherogenic index of plasma [log(triglycerides/HDL- cholesterol)]: theoretical and practical implications. Clin Chem 2004;50:1113-1115 (Pubitemid 38824219)
20. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;45(suppl 212):11-19
21. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676 (Pubitemid 19154942)
22. Brecher M, Leong RW, Stening G, et al. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007;68:597-603 (Pubitemid 46663043)
23. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100 (Pubitemid 32199865)
24. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007 May-Jun;13(suppl 1):1-68
25. Howlett MC, Lillie D. The Canadian Diabetes Association guidelines: putting the evidence first. CMAJ 2006;174:333-334 (Pubitemid 43235304)
26. Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology 2007;32:2561-2569 (Pubitemid 350126844)
27. Bonaccorsi A, Garattini S, Jori A. Studies on the hyperglycaemia induced by chlorpromazine in rats. Br J Pharmacol Chemother 1964;23:93-100
28. Dwyer DS, Lu XH, Bradley RJ. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res 2003;971:31-39 (Pubitemid 36412061)
29. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007;32:289-297 (Pubitemid 46106936)
30. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93